Shire Buys Fosrenol Patent Rights for Up to $31 M
Shire Pharmaceuticals Group Plc, the U.K.'s third-largest drugmaker, will spend up to $31 million to buy global patent rights to its kidney-failure drug Fosrenol from AnorMED, the company said....To view the full article, register now.
Already a subscriber? Click here to view full article